JP2019524836A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524836A5 JP2019524836A5 JP2019508963A JP2019508963A JP2019524836A5 JP 2019524836 A5 JP2019524836 A5 JP 2019524836A5 JP 2019508963 A JP2019508963 A JP 2019508963A JP 2019508963 A JP2019508963 A JP 2019508963A JP 2019524836 A5 JP2019524836 A5 JP 2019524836A5
- Authority
- JP
- Japan
- Prior art keywords
- unit dosage
- dosage form
- active agent
- therapeutically active
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 27
- 239000013543 active substance Substances 0.000 claims 16
- 238000010521 absorption reaction Methods 0.000 claims 12
- 239000003623 enhancer Substances 0.000 claims 12
- 102000003982 Parathyroid hormone Human genes 0.000 claims 5
- 108090000445 Parathyroid hormone Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 239000000199 parathyroid hormone Substances 0.000 claims 5
- 229960001319 parathyroid hormone Drugs 0.000 claims 5
- UQFYDAAKCZKDHS-UHFFFAOYSA-M sodium;4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate Chemical compound [Na+].OC1=CC(Cl)=CC=C1C(=O)NCCCC([O-])=O UQFYDAAKCZKDHS-UHFFFAOYSA-M 0.000 claims 5
- XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 claims 4
- 238000004503 metal oxide affinity chromatography Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 231100001126 band 3 compound Toxicity 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims 1
- 229940124532 absorption promoter Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 210000004051 gastric juice Anatomy 0.000 claims 1
- -1 hydroxy-4-chlorobenzoyl Chemical group 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022099609A JP7546622B2 (ja) | 2016-08-17 | 2022-06-21 | 活性薬剤の経口投与のための製剤 |
| JP2024016436A JP7736834B2 (ja) | 2016-08-17 | 2024-02-06 | 活性薬剤の経口投与のための製剤 |
| JP2025076671A JP2025114692A (ja) | 2016-08-17 | 2025-05-02 | 活性薬剤の経口投与のための製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662375989P | 2016-08-17 | 2016-08-17 | |
| US62/375,989 | 2016-08-17 | ||
| PCT/IL2017/050920 WO2018033927A1 (en) | 2016-08-17 | 2017-08-17 | Formulations for oral administration of active agents |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022099609A Division JP7546622B2 (ja) | 2016-08-17 | 2022-06-21 | 活性薬剤の経口投与のための製剤 |
| JP2024016436A Division JP7736834B2 (ja) | 2016-08-17 | 2024-02-06 | 活性薬剤の経口投与のための製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524836A JP2019524836A (ja) | 2019-09-05 |
| JP2019524836A5 true JP2019524836A5 (enExample) | 2020-09-17 |
| JP7530173B2 JP7530173B2 (ja) | 2024-08-07 |
Family
ID=61196521
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508963A Active JP7530173B2 (ja) | 2016-08-17 | 2017-08-17 | 活性薬剤の経口投与のための製剤 |
| JP2022099609A Active JP7546622B2 (ja) | 2016-08-17 | 2022-06-21 | 活性薬剤の経口投与のための製剤 |
| JP2024016436A Active JP7736834B2 (ja) | 2016-08-17 | 2024-02-06 | 活性薬剤の経口投与のための製剤 |
| JP2025076671A Pending JP2025114692A (ja) | 2016-08-17 | 2025-05-02 | 活性薬剤の経口投与のための製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022099609A Active JP7546622B2 (ja) | 2016-08-17 | 2022-06-21 | 活性薬剤の経口投与のための製剤 |
| JP2024016436A Active JP7736834B2 (ja) | 2016-08-17 | 2024-02-06 | 活性薬剤の経口投与のための製剤 |
| JP2025076671A Pending JP2025114692A (ja) | 2016-08-17 | 2025-05-02 | 活性薬剤の経口投与のための製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12239691B2 (enExample) |
| EP (1) | EP3500291A4 (enExample) |
| JP (4) | JP7530173B2 (enExample) |
| KR (4) | KR20230088854A (enExample) |
| CN (4) | CN109862906A (enExample) |
| AU (2) | AU2017311698B2 (enExample) |
| BR (1) | BR112019003136A2 (enExample) |
| CA (1) | CA3033259A1 (enExample) |
| IL (3) | IL312218B2 (enExample) |
| MX (1) | MX2019001850A (enExample) |
| NZ (1) | NZ751668A (enExample) |
| SG (1) | SG11201901070YA (enExample) |
| WO (1) | WO2018033927A1 (enExample) |
| ZA (1) | ZA201901370B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016128972A1 (en) * | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Formulations for oral administration of active agents with controlled absorption profile |
| MX2019001850A (es) * | 2016-08-17 | 2019-05-15 | Entera Bio Ltd | Formulaciones para administracion oral de principios activos. |
| US12303487B2 (en) * | 2018-11-19 | 2025-05-20 | Spoke Sciences, Inc. | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions |
| CN115209910A (zh) * | 2020-03-18 | 2022-10-18 | 四川海思科制药有限公司 | 口服药物组合物 |
| AU2023226092A1 (en) * | 2022-02-24 | 2024-10-03 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone |
| WO2023161936A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone |
| KR20240152915A (ko) * | 2022-02-24 | 2024-10-22 | 엔테라 바이오 리미티드 | 활성제의 경구 투여를 위한 산 중화 중합체를 포함하는 제형 |
| WO2025046589A1 (en) * | 2023-08-30 | 2025-03-06 | Entera Bio Ltd. | Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360793A (en) | 1993-05-24 | 1994-11-01 | Sterling Winthrop Inc. | Rafting antacid formulation |
| US6875856B2 (en) | 1993-09-24 | 2005-04-05 | Syntro Corporation | Recombinant infectious laryngotracheitis virus and uses thereof |
| CN1162917A (zh) | 1994-10-07 | 1997-10-22 | 伯温德药品服务公司 | 肠内涂层组合物，用其涂覆的方法和涂覆制品 |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| CA2220301C (en) | 1995-06-02 | 2006-02-21 | Alza Corporation | Osmotic device with delayed activation of drug delivery and complete drug release |
| JP3880093B2 (ja) | 1995-08-08 | 2007-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 錠剤 |
| JP3220373B2 (ja) | 1995-11-28 | 2001-10-22 | バイエル薬品株式会社 | 持続性ニフエジピン製剤 |
| IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| CN1228708A (zh) | 1996-09-04 | 1999-09-15 | 有限会社多特 | 经口给药用含肽药物组合物 |
| US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
| AU3240900A (en) | 1999-02-22 | 2000-09-04 | Emisphere Holdings, Inc. | Solid oral dosage form containing heparin or a heparinoid in combination with a carrier |
| EP1163209A4 (en) | 1999-02-26 | 2004-12-29 | Emisphere Tech Inc | COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS |
| NZ534409A (en) | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
| MXPA02004092A (es) | 1999-11-05 | 2003-02-12 | Emisphere Tech Inc | Compuestos y composiciones de acido fenilaminocarboxilico para administrar agentes activos. |
| AU1594801A (en) | 1999-11-12 | 2001-06-06 | Emisphere Technologies, Inc. | Liquid heparin formulation |
| DE60233803D1 (de) | 2001-08-17 | 2009-11-05 | Novartis Ag | 5-cnac zur oralen verabreichung von parathormonfragmenten |
| BR0214199A (pt) | 2001-11-13 | 2005-01-04 | Emisphere Tech Inc | Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração |
| CA2466863A1 (en) | 2001-11-29 | 2003-06-05 | Emisphere Technologies, Inc. | Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid |
| CA2469673A1 (en) * | 2001-12-19 | 2003-06-26 | Sanwa Kagaku Kenkyusho Co., Ltd. | Controlled release molded product |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US20050054557A1 (en) | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| AR040737A1 (es) | 2002-08-01 | 2005-04-20 | Novartis Ag | Administracion oral de calcitonina |
| JP2007525472A (ja) * | 2003-07-04 | 2007-09-06 | ニコメド ダンマーク エイピーエス | 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物 |
| JP2005281231A (ja) | 2004-03-30 | 2005-10-13 | Bioserentack Co Ltd | 小腸ターゲットタイプの経口ｄｄｓ製剤 |
| US20060052306A1 (en) | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
| US20060078623A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| JP2006111558A (ja) | 2004-10-14 | 2006-04-27 | Bioserentack Co Ltd | 多層構造を有する錠剤状の小腸粘膜付着性経口製剤 |
| JP2008520726A (ja) * | 2004-11-19 | 2008-06-19 | スミスクライン・ビーチャム・コーポレイション | 医薬製品 |
| US8110547B2 (en) | 2005-01-12 | 2012-02-07 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| JP5175553B2 (ja) * | 2005-02-01 | 2013-04-03 | エミスフェアー・テクノロジーズ・インク | 胃内滞留および制御放出型送達系 |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| JP5123471B2 (ja) | 2005-08-18 | 2013-01-23 | 帝人ファーマ株式会社 | 用量調整が容易な製剤 |
| EP2722054B1 (en) | 2005-09-06 | 2018-03-21 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| SI2952197T1 (sl) | 2005-10-26 | 2017-09-29 | Cydex Pharmaceuticals, Inc. | Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega |
| AU2006318815B2 (en) | 2005-11-17 | 2010-08-19 | Novartis Ag | Pharmaceutical composition |
| US20070178155A1 (en) | 2006-01-31 | 2007-08-02 | Jiang David Yihai | Preparation for gastric buoyant sustained drug release dosage form |
| BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| US8703821B2 (en) | 2006-04-18 | 2014-04-22 | Emisphere Technologies Inc. | Dialkyl ether delivery agents |
| EP2061440A2 (en) * | 2007-04-04 | 2009-05-27 | Sigmoid Pharma Limited | A pharmaceutical composition of tacrolimus |
| US20100303901A1 (en) | 2007-04-26 | 2010-12-02 | Eyal Shimoni | Oral delivery of proteins and peptides |
| JP2010539096A (ja) | 2007-09-11 | 2010-12-16 | オラヘルス コーポレーション | 咽喉、食道及び胃の治療のための局所的に活性である成分を放出する接着トローチ |
| WO2009080764A2 (en) | 2007-12-20 | 2009-07-02 | Abylnx N.V. | Oral or nasal administration of compounds comprising amino acid sequences |
| IT1393244B1 (it) * | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale |
| CN102123697B (zh) | 2008-08-18 | 2015-06-10 | 安特拉贝欧有限公司 | 用于口服给予蛋白质的方法和组合物 |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| EP2558106A1 (en) | 2010-04-16 | 2013-02-20 | Novartis AG | Methods and compositions for improving implant osseointegration |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| EP2747563A4 (en) | 2011-08-26 | 2015-06-24 | Aegis Therapeutics Llc | COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS |
| US9402877B2 (en) | 2011-11-04 | 2016-08-02 | Xion Pharmaceuticals Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
| WO2013189988A1 (en) | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| US9803731B2 (en) | 2014-04-24 | 2017-10-31 | American Axle & Manufacturing, Inc. | Actuator device having cam and follower and controller configured to employ rate-based methodology to identify positioning of follower on cam at predetermined location |
| EP2975118B1 (en) | 2014-07-16 | 2016-08-24 | Johann Wolfgang Goethe-Universität, Frankfurt am Main | Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone marrow donors |
| WO2016128972A1 (en) | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Formulations for oral administration of active agents with controlled absorption profile |
| MX2019001850A (es) | 2016-08-17 | 2019-05-15 | Entera Bio Ltd | Formulaciones para administracion oral de principios activos. |
| JP7419862B2 (ja) | 2020-02-14 | 2024-01-23 | 株式会社リコー | 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置 |
-
2017
- 2017-08-17 MX MX2019001850A patent/MX2019001850A/es unknown
- 2017-08-17 AU AU2017311698A patent/AU2017311698B2/en active Active
- 2017-08-17 US US16/326,213 patent/US12239691B2/en active Active
- 2017-08-17 WO PCT/IL2017/050920 patent/WO2018033927A1/en not_active Ceased
- 2017-08-17 EP EP17841226.8A patent/EP3500291A4/en active Pending
- 2017-08-17 CN CN201780064008.6A patent/CN109862906A/zh active Pending
- 2017-08-17 IL IL312218A patent/IL312218B2/en unknown
- 2017-08-17 NZ NZ751668A patent/NZ751668A/en unknown
- 2017-08-17 CN CN202311018541.2A patent/CN116850132A/zh active Pending
- 2017-08-17 IL IL321113A patent/IL321113A/en unknown
- 2017-08-17 CN CN202311014662.XA patent/CN116831978A/zh active Pending
- 2017-08-17 IL IL264880A patent/IL264880B2/en unknown
- 2017-08-17 KR KR1020237019713A patent/KR20230088854A/ko not_active Ceased
- 2017-08-17 SG SG11201901070YA patent/SG11201901070YA/en unknown
- 2017-08-17 CN CN202311014654.5A patent/CN116831977A/zh active Pending
- 2017-08-17 CA CA3033259A patent/CA3033259A1/en active Pending
- 2017-08-17 KR KR1020247016245A patent/KR102832565B1/ko active Active
- 2017-08-17 KR KR1020197007250A patent/KR20190039768A/ko not_active Ceased
- 2017-08-17 BR BR112019003136A patent/BR112019003136A2/pt active Search and Examination
- 2017-08-17 JP JP2019508963A patent/JP7530173B2/ja active Active
- 2017-08-17 KR KR1020247029460A patent/KR102832566B1/ko active Active
-
2019
- 2019-03-05 ZA ZA2019/01370A patent/ZA201901370B/en unknown
-
2022
- 2022-06-21 JP JP2022099609A patent/JP7546622B2/ja active Active
-
2024
- 2024-02-06 JP JP2024016436A patent/JP7736834B2/ja active Active
- 2024-08-20 AU AU2024211004A patent/AU2024211004B2/en active Active
- 2024-08-29 US US18/818,691 patent/US20240415936A1/en active Pending
-
2025
- 2025-05-02 JP JP2025076671A patent/JP2025114692A/ja active Pending